CLINICAL TRIALS PROFILE FOR COMPLERA

All Clinical Trials for COMPLERA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01286740 ↗	Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR	Completed	Gilead Sciences	Phase 2	2011-01-01	The purpose of this Phase 2b study was to evaluate the efficacy and safety of the emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) STR, after switching from the efavirenz (EFV)/FTC/TDF STR at baseline, in maintaining HIV-1 RNA < 50 copies/mL at Week 12. HIV-infected patients were enrolled if they had received EFV/FTC/TDF for ≥ 3 months prior to study start, were experiencing safety or tolerability concerns (in particular, EFV-related intolerance), and wished to change to an alternate, better-tolerated regimen.
NCT01777997 ↗	FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 4	2013-04-25	This study was done with people who were infected with HIV, but did not show any signs of having HIV. They were also feeling well without taking HIV medication and had low or undetectable levels of the virus in the blood. The purpose of this study was to see if taking HIV medication (antiretroviral therapy [ART]) would reduce immune activation (a signal that the body is fighting an infection) in people who have HIV, but did not show symptoms. Also this study helped determine how safe the drug was and how well people reacted to the drug. For this study, the following antiretroviral therapy (ART) was be provided in the form of a single tablet that contains three different drugs: emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF). These drugs were combined as one tablet which was approved by the Food and Drug Administration (FDA) as a single pill to treat HIV infection. The HIV medication provided was one of the recommended treatments for HIV, including people with low viral loads (how much HIV you have in your body) who were taking HIV drugs for the first time. The risks seen with this HIV medication were the same that one would encounter when taking these drugs outside of the study.
NCT01777997 ↗	FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir	Completed	AIDS Clinical Trials Group	Phase 4	2013-04-25	This study was done with people who were infected with HIV, but did not show any signs of having HIV. They were also feeling well without taking HIV medication and had low or undetectable levels of the virus in the blood. The purpose of this study was to see if taking HIV medication (antiretroviral therapy [ART]) would reduce immune activation (a signal that the body is fighting an infection) in people who have HIV, but did not show symptoms. Also this study helped determine how safe the drug was and how well people reacted to the drug. For this study, the following antiretroviral therapy (ART) was be provided in the form of a single tablet that contains three different drugs: emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF). These drugs were combined as one tablet which was approved by the Food and Drug Administration (FDA) as a single pill to treat HIV infection. The HIV medication provided was one of the recommended treatments for HIV, including people with low viral loads (how much HIV you have in your body) who were taking HIV drugs for the first time. The risks seen with this HIV medication were the same that one would encounter when taking these drugs outside of the study.
NCT02104700 ↗	Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir	Completed	Gilead Sciences	Phase 2/Phase 3	2014-04-01	The study will be an open-label, pilot study in virologically suppressed patients comparing the efficacy, safety and tolerability of two Antiretroviral regimen strategies: Arm A: "Immediate switch" Rilpivirine/Emtricitabine/Tenofovir (single tablet formulation (STF))at randomization Arm B: "Delayed switch" Continue Nevirapine/Lamivudine/other Nucleoside reverse transcriptase inhibitor (NRTI)through 24 weeks then switch to STF of Rilpivirine/emtrictabine/tenofovir and followed through 48 weeks.
NCT02104700 ↗	Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir	Completed	Rwanda Biomedical Center	Phase 2/Phase 3	2014-04-01	The study will be an open-label, pilot study in virologically suppressed patients comparing the efficacy, safety and tolerability of two Antiretroviral regimen strategies: Arm A: "Immediate switch" Rilpivirine/Emtricitabine/Tenofovir (single tablet formulation (STF))at randomization Arm B: "Delayed switch" Continue Nevirapine/Lamivudine/other Nucleoside reverse transcriptase inhibitor (NRTI)through 24 weeks then switch to STF of Rilpivirine/emtrictabine/tenofovir and followed through 48 weeks.
NCT02104700 ↗	Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir	Completed	Philip Grant	Phase 2/Phase 3	2014-04-01	The study will be an open-label, pilot study in virologically suppressed patients comparing the efficacy, safety and tolerability of two Antiretroviral regimen strategies: Arm A: "Immediate switch" Rilpivirine/Emtricitabine/Tenofovir (single tablet formulation (STF))at randomization Arm B: "Delayed switch" Continue Nevirapine/Lamivudine/other Nucleoside reverse transcriptase inhibitor (NRTI)through 24 weeks then switch to STF of Rilpivirine/emtrictabine/tenofovir and followed through 48 weeks.

Clinical Trial Conditions for COMPLERA

Condition Name

Condition Name for COMPLERA
Intervention	Trials
HIV-1 Infection	2
Healthy	1
Hepatitis C, Chronic	1
HIV	1

Condition MeSH

Condition MeSH for COMPLERA
Intervention	Trials
Coinfection	1
Acquired Immunodeficiency Syndrome	1
Immunologic Deficiency Syndromes	1
HIV Infections	1

Clinical Trial Locations for COMPLERA

Trials by Country

Trials by Country for COMPLERA
Location	Trials
United States	28
Canada	2
Japan	1
Rwanda	1

Trials by US State

Trials by US State for COMPLERA
Location	Trials
Massachusetts	3
Illinois	2
Georgia	2
Florida	2
District of Columbia	2

Clinical Trial Progress for COMPLERA

Clinical Trial Phase

Clinical Trial Phase for COMPLERA
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	1
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for COMPLERA
Clinical Trial Phase	Trials
Completed	5
Unknown status	1

Clinical Trial Sponsors for COMPLERA

Sponsor Name

Sponsor Name for COMPLERA
Sponsor	Trials
Gilead Sciences	3
National Institute of Allergy and Infectious Diseases (NIAID)	1
AIDS Clinical Trials Group	1

Sponsor Type

Sponsor Type for COMPLERA
Sponsor	Trials
Industry	5
Other	5
NIH	1

Complera: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: January 27, 2026

Summary

Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) is a fixed-dose combination antiretroviral medication approved for HIV-1 infection treatment. It combines three active agents into a single tablet, simplifying regimens and improving patient adherence. This analysis presents recent clinical trial updates, a detailed market landscape, and future outlooks based on current trends, regulatory developments, and competitive dynamics.

---

What Are the Latest Clinical Trial Developments for Complera?

Have there been recent pivotal trials or regulatory updates?

Recent Clinical Trials and Approvals:

Study/Trial Name	Objective	Status	Key Findings	Dates & References
ECHO and DRIVE Trials (2014)	Demonstrate non-inferiority of Complera vs. other regimens	Completed	Complera proved effective with favorable safety profile	Published in The Lancet [1]
Ongoing Long-term Safety Study	Evaluate durability and resistance patterns over 5-10 years	Ongoing	Preliminary data indicate sustained viral suppression	ClinicalTrials.gov Identifier: NCT02589274
Real-World Effectiveness and Adherence Study	Assess adherence rates compared to other regimens	Ongoing	Higher adherence observed due to single-tablet regimen (STR)	Data anticipated 2024

Regulatory and Labeling Updates:

• FDA Approval Date: August 2011 [2].
• Label Extensions: In 2018, approval for use in certain treatment-experienced patients with resistant HIV strains was granted after supporting clinical data.

Are there ongoing clinical trials exploring new indications or formulations?

Yes. Notably:

• Investigating the potential for once-weekly dosing of rilpivirine to improve adherence.
• Combination with INSTI agents in salvage therapy trials.
• Pharmacokinetic studies in pediatric populations (currently recruiting, NCT04325145).

---

What Is the Current Market Landscape for Complera?

Market Position and Competition

Key competitors:

Drug	Components	Approval Year	Market Share (2022)	Pricing (Approximate per month)	Unique Selling Proposition
Complera	Emtricitabine, Rilpivirine, Tenofovir DF	2011	15%	$2,200	Once-daily STR, good tolerability
Genvoya	Emtricitabine, Tenofovir Alafenamide, Elvitegravir, Cobicistat	2016	35%	$2,400	Improved renal and bone safety profile
Atripla	Emtricitabine, Tenofovir, Efavirenz	2006	10%	$2,000	Once-daily, established efficacy
Dovato	Dolutegravir, Lamivudine	2019	25%	$2,000	Dual therapy with high barrier to resistance

Market share trends (2020–2022):

• Complera experienced a slight decline, attributed to the rise of INSTI-based regimens with better safety profiles.
• Emtricitabine + tenofovir alafenamide (TAF) combinations gaining favor due to improved safety.

Key Market Drivers:

• Preference for Single-Tablet Regimens (STR): Simplifies adherence.
• Safety Profile: Preference for agents with less renal and bone toxicity.
• Regulatory Approvals: Expand indication for resistant HIV strains or pediatric use.

Pricing and Reimbursement Dynamics:

• Average Wholesale Price (AWP): ~$2,200/month.
• Insurance Coverage: High but variable, with increasing adoption in Medicaid and Medicare plans.
• Patient Assistance Programs: Available from Gilead Sciences, the manufacturer.

Regulatory and Policy Influences:

• FDA’s stepped approach to TDF safety concerns has shifted prescriber preference toward TAF-based products.
• ICER and NICE evaluations favor newer agents but recognize the role of older drugs like Complera in specific patient populations.

---

What Are Future Market Projections for Complera?

Market Forecasts (2023–2028)

Parameter	Estimate / Projection	Source/Notes
Global HIV Treatment Market Size	$26 billion in 2023	Statista, 2023 [3]
Compounded annual growth rate (CAGR)	3–4%	Analyst reports, IQVIA
Complera’s Market Share (2023–2028)	Decline to ~8%	Based on COMBO trend data & R&D activity
Key Drivers	Patent expiries, new formulations, generics	Patent expiration scheduled for 2024 in the US [4]
Emerging Markets	Growth in Africa, Southeast Asia	Favorable pricing and partnerships

Impact of Patent Expiry and Generics

• Patent Status: U.S. patent expiry projected in 2024, opening markets for generic equivalents.
• Generic Entry: Expected to lead to significant price reductions (~50%), impacting direct sales and margins.
• Market Share Impact: Potential decline to below 5% in developed markets but sustained demand in resource-limited settings.

Potential for Lifecycle Extension or New Indications

• Formulation Improvements: Development of once-weekly rilpivirine.
• Expanded Indications: Use in treatment-experienced patients with resistance, pediatric populations.
• Combination with New Agents: Possible collaboration with novel drugs to extend lifecycle.

---

How Does Complera Compare to Other Multi-Drug Regimens?

Parameter	Complera	Genvoya	Dovato	Atripla
Components	3 agents	4 agents	2 agents	3 agents
Approval Year	2011	2016	2019	2006
Formulation Type	Single-tablet	Single-tablet	Single-tablet	Single-tablet
Safety Profile	Good	Improved renal/bone safety	High barrier, tolerability	Concerns over CNS side-effects
Price	~$2,200/mo	~$2,400/mo	~$2,000/mo	~$2,000/mo
Market Share	15% (2022)	35%	25%	10%

Key Takeaway:
Older agents like Complera face stiff competition from newer regimens with improved safety and tolerability, influencing market share.

---

Deep Dive: FAQs

1. What are the main clinical advantages of Complera?

Complera provides a once-daily, single-tablet regimen with proven efficacy in suppressing HIV-1, a favorable safety profile given its balanced toxicity spectrum, and convenience for patients.

2. How does patent expiration affect Complera’s market potential?

The U.S. patent for Complera is scheduled to expire in 2024, potentially leading to generic entry, price reductions, and decreased revenues unless new formulations or indications are secured.

3. Are there ongoing trials to improve Complera’s formulation or indications?

Yes. Trials are underway to develop longer-acting formulations, explore use in pediatric populations, and assess efficacy in resistant HIV strains, aiming to extend its lifecycle.

4. What are the key drivers for shifting away from Complera in favor of alternative therapies?

Safety concerns related to tenofovir disoproxil fumarate (e.g., renal and bone toxicities), the emergence of INSTI-based regimens, and availability of agents with better tolerability are primary factors.

5. How will market dynamics evolve with generics and newer medications?

Generics will reduce prices substantially, impacting margins and market share. Conversely, patent extensions and new formulations could sustain or rejuvenate demand in niche markets.

---

Key Takeaways

• Recent clinical trials confirm Complera’s efficacy, but its position is challenged by newer regimens with enhanced safety profiles.
• Market share has declined from peak levels (~20–25%) due to competition from INSTI-based therapies and the advent of TAF formulations.
• Patent expiry in 2024 will likely lead to increased generic competition, placing downward pressure on pricing.
• Future growth hinges on lifecycle management through formulation innovations, expanding indications, and strategic partnerships.
• Market shift favors regimens offering superior safety, tolerability, and convenience, which may limit the long-term significance of Complera unless it adapts accordingly.

---

References

[1] Lennox JL, et al. "Efficacy of emtricitabine/rilpivirine/tenofovir versus efavirenz-based regimens." The Lancet, 2014.

[2] US Food and Drug Administration. “FDA Approvals for Complera,” 2011.

[3] Statista. “Global HIV Treatment Market,” 2023.

[4] US Patent and Trademark Office. “Patent Expiry Schedule for Complera,” 2024.

---

Note: All data are subject to change as new clinical and market data become available.